Fulgent Genetics, Inc. beat EPS estimates 81% of the time across 16 reported quarters (13 beats, 3 misses), averaging +22.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.79 | $-0.88 | -11.4% | Miss | Q2 FY26 call |
| Q1 FY26 | $-0.53 | $-0.64 | -20.8% | Miss | Q1 FY26 call |
| Q4 FY25 | $-0.27 | $-0.11 | +59.3% | Beat | Q4 FY25 call |
| Q3 FY25 | not reported | $-0.16 | not reported | not reported | |
| Q2 FY25 | $-0.56 | $-0.25 | +55.4% | Beat | |
| Q1 FY25 | $-0.50 | $-0.30 | +40.0% | Beat | |
| Q4 FY24 | $-0.40 | $-0.23 | +42.5% | Beat | |
| Q3 FY24 | not reported | $-0.05 | not reported | not reported | |
| Q2 FY24 | not reported | $-0.22 | not reported | not reported | |
| Q1 FY24 | $-0.58 | $-0.38 | +34.5% | Beat | |
| Q4 FY23 | not reported | $-0.02 | not reported | not reported | |
| Q3 FY23 | $-0.61 | $-0.43 | +29.5% | Beat |
Back to FLGT overview · FLGT holders · FLGT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.